{
  "pmcid": "7270872",
  "sha256": "7d559a45c0d93a9590ceabe10bc0b892a973268ac411f529f35d2f4de5a3cbca",
  "timestamp_utc": "2025-11-09T16:12:46.790043+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.413032192819824,
    "reading_ease": 35.46297657171752,
    "word_count": 349
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Design, Setting, and Participants: For this randomized clinical trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "patients with established type 2 diabetes and microalbuminuria were recruited from a single center from April 1, 2013, through March 31, 2016, with a 5-year follow-up"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with established type 2 diabetes and microalbuminuria were recruited from a single center"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized 1:1 to receive best medical treatment (n = 49) or RYGB (n = 51)"
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective: To compare the albuminuria-lowering effects of Roux-en-Y gastric bypass (RYGB) surgery vs best medical treatment"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was remission of albuminuria (uACR <30 mg/g)."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomized 1:1"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 100 patients (mean [SD] age, 51.4 [7.6] years; 55 [55%] male) were randomized: 51 to RYGB and 49 to best medical care."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "A total of 100 patients (mean [SD] age, 51.4 [7.6] years; 55 [55%] male) were randomized: 51 to RYGB and 49 to best medical care."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Remission of albuminuria occurred in 55% of patients (95% CI, 39%-70%) after best medical treatment and 82% of patients (95% CI, 72%-93%) after RYGB ( P = .006)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No difference in the rate of serious adverse events was observed."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: ClinicalTrials.gov Identifier: NCT01821508"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}